Once-monthly octreotide provides sustained acromegaly control with fewer injections

BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.
There remains an unmet need for convenient therapies for acromegaly, which is characterized by overproduction of growth hormone and insulin-like growth factor I, according to Diego Ferone, MD, PhD, full professor of endocrinology in the department of internal medicine and medical specialties at the University of Genova, Italy. A key treatment goal

BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.
There remains an unmet need for convenient therapies for acromegaly, which is characterized by overproduction of growth hormone and insulin-like growth factor I, according to Diego Ferone, MD, PhD, full professor of endocrinology in the department of internal medicine and medical specialties at the University of Genova, Italy. A key treatment goal